RxDoctor Payments Data

Robert Wechsler, MD

Clinical Neurophysiology · Boise, IDNPI 1962498568

Payments from drug & device makers

$1,640,336in general payments, 2019–2025

Across 1,076 payments — averaging $1524.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$429K
  • Eisai Inc.$317K
  • UCB, Inc.$203K
  • UCB SA$140K
  • Aquestive Therapeutics, Inc.$134K
  • Sunovion Pharmaceuticals Inc.$89K
  • plus $329K from 33 others
$305,122in research payments, 2019–2025

Across 3 payments — averaging $101,707 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$305K

What the payments were for

  • Consulting fees$102,01915%
  • Speaking & faculty fees$518,65374%
  • Travel & lodging$59,0018%
  • Food & beverage$19,3343%
  • Education$5300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$57,680
Medicare patients
238
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)49$294,382
XcopriCenobamate56$92,842
Lamictal XrLamotrigine32$69,466
KeppraLevetiracetam23$29,565
TrileptalOxcarbazepine17$20,444
Lamictal OdtLamotrigine11$19,826
BriviactBrivaracetam11$15,712
FelbatolFelbamate12$14,521
FycompaPerampanel11$13,125
Lamotrigine ErLamotrigine30$13,081
Levetiracetam ErLevetiracetam36$5,755
Levetiracetam118$4,495
Lacosamide28$2,060
Zonisamide30$731
Lamotrigine60$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$428,871$92,84256 claims
UCB SAKeppra$140,237$29,56523 claims
UCB, Inc.Briviact$203,122$15,71211 claims
Eisai Inc.Fycompa$317,116$13,12511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →